Instituto Ramón y Cajal de Investigación Sanitaria
Información de contacto
- A. Biotecnología Sanitaria
- Campos de actividad
- Biofármacos
- Biomarcadores
- Dispositivos médicos
- Drug development
- Drug discovery
- Screening
- Terapia génica
- Vacunas
- Áreas terapéuticas
- Analgesia / Dolor
- Dermatología
- Desórdenes musculoesqueléticos
- Enfermedades cardiovasculares y sistema circulatorio
- Enfermedades genéticas y raras
- Enfermedades infecciosas
- Enfermedades inflamatorias
- Ginecología y tocología
- Inmunología
- Odontología
- Oftalmología y optometría
- Oncología
- Sangre y sistema linfático
- Sistema digestivo y hepatología
- Sistema genitourinario y riñón
- Sistema nervioso central
- Sistema respiratorio y pulmonar
- Trastornos metabólicos / Endocrinología
- D. Servicios
- Servicios de I+D
- Bioinformática
- Genómica
- Metabolómica
- Proteómica
The Ramon y Cajal Institute for Biohealth Research (IRYCIS) is a large multidisciplinary organization which integrates scientific and clinical researchers, physicians, and other technical staff from the hospital.
The IRYCIS' aim is to join the knowledge, resources and initiatives of their members, leading to real advances for disease's prevention and treatment, and the improvement of diagnostics technologies.
The research groups of IRYCIS are classified in four major areas:
- Neuroscience and Sense Organs
- Microbiology, Immunology and Infection
- Systemic Patology and Cancer
- Clinical Epidemiology
The Institute led by its Innovation Unit (IU), aims to transfer the research and innovation beyond its walls, and to participate in an european open innovation context contributing to improve patient care and provide new solutions for unmet medical needs.
IRYCIS has a portfolio consisting of patents to out license, services to offer and research projects looking for industrial collaboration. The Institute also wants to open the door to new Horizon 2020 collaborations.
Biotech Sanitaria
| Producto / Servicio | Tipo | Área terapéutica | Fase de desarrollo |
|---|---|---|---|
| New compound for the treatment of isquemical stroke | Biodrugs/ Drugs | Sistema nervioso central | R&D |
| New aptamers for the treatment of stroke | Biodrugs/ Drugs | Sistema nervioso central | P II |
| Producto / Servicio | Tipo | Fase de desarrollo |
|---|---|---|
| miRNA platform | Screening/Drug Discovery | Clinical Validation |
| Producto / Servicio | Área terapéutica | Fase de desarrollo |
|---|---|---|
| Telemedicine platforms | Oncología | Preclinical |